Cipla is currently trading at Rs. 393.00, up by 2.95 points or 0.76% from its previous closing of Rs. 390.05 on the BSE.
The scrip opened at Rs. 392.00 and has touched a high and low of Rs. 394.00 and Rs. 390.20 respectively. So far 41,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 450.00 on 16-Sep-2013 and a 52 week low of Rs. 354.40 on 01-Mar-2013.
Last one week high and low of the scrip stood at Rs. 395.80 and Rs. 382.95 respectively. The current market cap of the company is Rs. 31,554 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.70% and 27.46% respectively.
Cipla’s wholly owned subsidiary - Cipla Holding B.V., has acquired 100% stake in Celeris d.o.o., Croatia. Celeris d.o.o. is the distributor of company’s products in Croatia.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
The company has reported 24.79% fall in its net profit at Rs 376.03 crore for the second quarter ended September 30, 2013 as compared to Rs 500.01 crore for the same quarter in the previous year. However, total income of the company has increased by 6.59% at Rs 2411.96 crore for quarter under review as compared to Rs 2262.74 crore for the quarter ended September 30, 2012
The scrip opened at Rs. 392.00 and has touched a high and low of Rs. 394.00 and Rs. 390.20 respectively. So far 41,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 450.00 on 16-Sep-2013 and a 52 week low of Rs. 354.40 on 01-Mar-2013.
Last one week high and low of the scrip stood at Rs. 395.80 and Rs. 382.95 respectively. The current market cap of the company is Rs. 31,554 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.70% and 27.46% respectively.
Cipla’s wholly owned subsidiary - Cipla Holding B.V., has acquired 100% stake in Celeris d.o.o., Croatia. Celeris d.o.o. is the distributor of company’s products in Croatia.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
The company has reported 24.79% fall in its net profit at Rs 376.03 crore for the second quarter ended September 30, 2013 as compared to Rs 500.01 crore for the same quarter in the previous year. However, total income of the company has increased by 6.59% at Rs 2411.96 crore for quarter under review as compared to Rs 2262.74 crore for the quarter ended September 30, 2012
No comments:
Post a Comment